Network Connection
Network Connection Seamus O’Neil, chief executive of the Academic Health Science Network for the North East and North Cumbria, on bridging the gap between pharma and the NHS What is your background and current role?I am currently the chief executive of the Academic Health Science Network for the North East and North Cumbria (NENC). My background is in NHS research management and before that I was a clinical scientist within the NHS (in genetics). What does your day-to-day work involve?Managing people, budgets and programmes. However, it is more exciting than it sounds. The people are fabulous, the ...
Birth Right
Birth Right The Zika outbreak has brought the issue of congenital anomalies to the forefront of the science community and the public’s mind. We ask Helen Dolk, Professor of Epidemiology at the University of Ulster, about the challenges of working in this areaWhat is your background and current role?I have been working for over 30 years on epidemiologic research relating to pregnancy, congenital anomalies or health effects of environmental exposures.  For 15 years, until recently, I was project leader of EUROCAT – European Surveillance of Congenital Anomalies and director of the associated WHO ...
Building blocks
Building blocks World-leading cancer researcher and entrepenuer Professor Tony Kouzarides offer some advice on connecting academia and pharma, setting up R&D companies and juggling several jobs at onceWhat is your background?I’ve always been interested in cancer, especially the human genes that cause it. My basic interest is molecular mechanisms of cancer, and that’s what my lab works on.Essentially I’ve been working on epigenetics for the last two decades. Twenty years ago my lab found one of the first enzymes that modify histone proteins – CBP – and had the first evidence that it was involved in cancer ...
New to the market
New to the market What does the industry have in store for aspiring marketers? We ask last year’s New Marketer of the Year, Thom RenwickWhat is your background and current role?I studied at King’s College London and Cranfield School of Management then took up a graduate role in the sales team at Roche. This was a great platform for pharmaceutical marketing as it gave me an understanding of the healthcare professional from an on-the-ground perspective, and insight into how to add value for them.I’m currently a brand manager at Roche, working on prelaunch brands in oncology. One of the great things about the ...
Talking about a revolution
Talking about  a revolution We live in exciting times of cutting-edge science, truly innovative new medicines and positive changes towards patient-centricity, says Janssen’s Jane GriffithsWhat is your current role?As Company Group Chairman for Janssen EMEA I am responsible for the commercial group in the region. How do you start your day?I get up early, take my dog for a quick walk (trying to increase my steps) then check my diary to get my head around the day ahead. After that, I head for the office or Heathrow airport.  What are the main issues in oncology at the moment?The main issue is that cancer still ...
Mission possible
Mission possible For more than 20 years, John Crowley has made it his mission to discover ever-more effective medicines to treat devastating rare genetic disordersDeveloping medicines for rare diseases requires an entirely different mindset, says John Crowley, chairman and CEO of rare disease company Amicus Therapeutics. “Developing drugs in rare diseases is very different from more prevalent disorders – the clinical studies are very small, you have different endpoints and biomarkers, different regulatory paradigms and different types of sales and marketing, plus the focus on the patient is intense. It takes ...
SmartPeople: Mr NICE Guy
SmartPeople: Mr NICE Guy One day a month, MSD's Paul Robinson helps to make decisions that affect tens of thousands of patients. He sits on one of NICE's Technology Appraisal Committees, a group of 15-20 healthcare professionals, NHS managers and patient representatives who decide which drugs the NHS in England will pay for and which it won't"When I tell people that I sit on a NICE committee but also work for a pharma company, eyebrows sometimes shoot up," says Paul, executive director, scientific medical and patient perspective at Merck Sharp and Dohme. "But what I believe I bring to the table is my deep ...
SmartPeople: Growth spurt
SmartPeople: Growth spurt After spending most of his career in the US, Takeda UK managing director Adam Zaeske arrived on our shores last year intent on transforming the company into an agile speciality businessWhat is your current role?I am managing director for the UK and Ireland business with responsibility to lead the commercial organisation – for me, that means bringing products to market that serve patients. I've been with Takeda for 12 years, in a number of roles, starting in product planning then leading teams in marketing, sales and market access, the three legs of the commercial stool. Prior to Takeda I was ...
SmartPeople: Padraic Dempsey
SmartPeople: Padraic Dempsey Uniphar’s Padraic Dempsey offers insights into his working day, opinions on the UK and Ireland industries and a sneak peek into his pastWhat is your current role and how did you get there?I joined Uniphar two years ago as managing director of manufacturer services, a €700 million business that first entered the UK market with the acquisition of Star, the market-leading outsourcing and resourcing company. By leveraging Star’s platform we have built a fully integrated manufacturing services business for the UK and Ireland that combines supply chain, outsourcing and resourcing, nurse services ...
SmartPeople: Erik Nordkamp
SmartPeople: Erik Nordkamp The managing director of Pfizer UK explains how he hopes to work with the government and NHS to advance healthcare in BritainPressure on both the NHS and the industry has increased tremendously over the last 15 years. Both have productivity challenges, which is why there needs to be a robust dialogue and strong relationship between pharmaceutical companies, government and the NHS to ensure an effective, efficient and sustainable healthcare system. As well as ensuring a continued supply of our existing medicines to UK patients and developing the medicines of the future, I’m really focused ...

Latest Jobs

Key Customer Manager- Thames Valley South East England Medical Sales Representative Negotiable
Product Specialist London, Europe Business Development Car
Product Specialist London, Europe Business Development 25000 - 30000 pa

About Pharmatimes

PharmaTimes Media’s recruitment hub offers the widest range of career opportunities for the pharmaceutical and healthcare industries.

Candidates benefit from an effective and efficient service designed to offer all that they need to seek new career opportunities.

Contact Anna Yeardley to place your job advertisement

Anna Yeardley - Business Development Manager
Tel: +44 (0)20 7240 6999
PharmaTimes Media Limited
8 – 10 Dryden Street
Covent Garden

Telephone: +44 (0)7240 6999

Upload your CV quickly

Upload your CV to our secure server & send it to jobs whenever you wish. You can also make your details available to Employers & Recruiters (confidential or named) which means they can find you, as well as you finding them!

Working in Healthcare - News and advice

Pharma Job News

October Movers
October Movers GSK has appointed Emma Walmsley as its CEO designate. She will succeed Andrew Witty as GSK CEO when he retires on 31 March 2017. Emma is currently CEO of GSK Consumer Healthcare, established in 2015 following completion of GSK’s three-part transaction with Novartis. Prior to this, Emma was president of GSK Consumer Healthcare and has been a member of GSK’s Corporate Executive Team since 2011. Emma joined GSK in 2010 from L’Oreal where, over the course of her 17-year career, she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in ...
Movers September
Movers September Mike Hannay is the new managing director of the East Midlands Academic Health Science Network (EMAHSN). He will play a key role at the heart of the East Midlands' healthcare system, working with partners across health, academic, social care, industry and third sectors to build collaboration and spread health innovation at pace and scale. Mike has joined EMAHSN from ThermoFisher Scientific, where he was vice-president for the UK BioPharma Services division, a role that  built upon his significant experience both nationally and internationally, including vice-president of medicines ...
Movers July/August
Movers July/August Novo A/S has appointed Kasim Kutay as its new CEO. Kasim started his career at Morgan Stanley, where he spent 18 years advising mainly healthcare companies. He is currently co-head of Europe at Moelis & Company and also serves on the bank's management committee. Novo A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company in the Novo Group and responsible for managing the Foundation's assets.Envigo has appointed Dr Adrian Hardy as president and CEO. Adrian joined Envigo in 2002 and has held various roles of increasing ...

This website uses cookies. Read our cookie policy for more information. By continuing to browse this site you are agreeing to our use of cookies.

Latest Job Listings